Bristol-Myers Squibb (BMY) declared a quarterly dividend of $0.57 per share, or $2.28 annualized.The dividend will be payable on November 1, 2023, to stockholders of record on October 6,...
The US Food and Drug Administration (FDA) has approved GlaxoSmithKline's (NYSE:GSK) novel treatment, Ojjaara (momelotinib), for adults with intermediate- or high-risk myelofibrosis and...
Samsung Biologics announced today a new agreement with Bristol Myers Squibb (BMY) for large-scale manufacturing of a Bristol Myers Squibb commercial antibody cancer drug substance.Bristol...
An analyst from HSBC maintained Bristol-Myers Squibb (NYSE: BMY) at 'reduce' with a price target of $55.00 from a prior price target of $56.00. Prior to this rating, Bristol-Myers Squibb...
An analyst from TD Cowen maintained Bristol-Myers Squibb (NYSE: BMY) at 'market perform' with a price target of $67.00 from a prior price target of $80.00. Prior to this rating,...
TD Cowen analyst lowered to $67."
Bristol-Myers Squibb & Co (NYSE: BMY) announced its ambitious plan to double the number of treatments undergoing clinical trials in the next 18 months, focusing primarily on targeted...
Bristol Myers Squibb (BMY) is today holding a Research and Development (R&D) Day in New York to discuss the company’s R&D strategy and capabilities and to provide insight into its robust...
Goldman Sachs has upgraded its rating for late-stage biotech company Geron (NASDAQ:GERN) Corporation (NASDAQ:GERN) from neutral to buy, maintaining a price target of $4, which suggests a...
Bristol Myers Squibb & Co (NYSE: BMY) announced six-year results from Part 1 of the Phase 3 CheckMate -227 trial, which continues to demonstrate long-term, durable survival benefits of...
Bristol Myers Squibb (BMY) today announced six-year results from Part 1 of the Phase 3 CheckMate -227 trial, which continues to demonstrate long-term, durable survival benefits of Opdivo...
Futurize and AstraZeneca (LON:AZN) have officially launched the pioneering HealthTech incubator program, FuturizeU, co-funded by Bristol Myers Squibb, running from September 12 to November...
Bristol Myers Squibb (BMY) today announced results from a Phase 2 study evaluating BMS-986278, a potential first-in-class, oral, lysophosphatidic acid receptor 1 (LPA1) antagonist in...
Bristol Myers Squibb Co (NYSE: BMY) faces fresh allegations in a recent lawsuit, accused of employing deceptive patents and illicit strategies to preserve its dominant position in the blood...
New York, USA, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Psoriatic Arthritis Market to Register Immense Growth by 2032, Assesses DelveInsight | Key Companies to Look Out - Bristol-Myers Squibb,...
Merck, Johnson & Johnson and Amgen are among the first drugmakers to have products chosen for a contentious initiative to rein in prescription-drug costs.
On Monday, the FDA approved Bristol Myers Squibb Co's (NYSE: BMY) Reblozyl (luspatercept-aamt) for anemia without previous erythropoiesis-stimulating agent use (ESA-naïve) in adult patients...
The Biden administration has today taken a significant step towards addressing the affordability of prescription drugs for older Americans. Recent changes to the Medicare bill allow Medicare...
Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Reblozyl® (luspatercept-aamt) for the treatment of anemia without previous...
Bristol Myers Squibb (NYSE:BMY) today announced new long-term follow-up results from two Phase 3 studies evaluating CAMZYOS® (mavacamten), a first-in-class cardiac myosin inhibitor, in adult...
Bristol Myers Squibb (NYSE:BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) as a monotherapy for the adjuvant treatment of adults and adolescents 12...
Bristol Myers Squibb (BMY) today announced updated results from the registrational TRIDENT-1 study, demonstrating that repotrectinib, a next-generation ROS1/TRK tyrosine kinase inhibitor...
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received a De Novo approval by the U.S. Food and Drug Administration (FDA) for...
Bristol Myers Squibb (BMY) today announced that it has entered into accelerated share repurchase (ASR) transactions under agreements with each of Bank of America, N.A., Citibank, N.A.,...
An analyst from Morgan Stanley maintained Bristol-Myers Squibb (NYSE: BMY) at 'underweight' with a price target of $57.00 from a prior price target of $59.00. Prior to this rating,...
An analyst from Wells Fargo maintained Bristol-Myers Squibb (NYSE: BMY) at 'equal weight' with a price target of $65.00 from a prior price target of $78.00. Prior to this rating,...
An analyst from BMO Capital maintained Bristol-Myers Squibb (NYSE: BMY) at 'outperform' with a price target of $79.00 from a prior price target of $87.00. Prior to this rating,...
Investing.com - Bristol-Myers Squibb (NYSE: BMY) reported second quarter EPS of $1.75, $0.23 worse than the analyst estimate of $1.98. Revenue for the quarter came in at $11.2B versus the...
Immatics N.V. (IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that...
Bristol Myers Squibb (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo...
HSBC analysts initiated research coverage of Biopharma stocks with a predominantly positive view. The analysts argue that “a loss of exclusivity and drug pricing regulations are likely to...
An analyst from HSBC initiated coverage of Bristol-Myers Squibb (NYSE: BMY) at 'reduce' with a price target of $56.00. Prior to this rating, Bristol-Myers Squibb had 13 buy ratings, 13...
Bristol Myers Squibb (NYSE:BMY) today announced that the sub-study of the Phase 3 CheckMate -901 trial met the dual primary endpoints of overall survival (OS) and progression-free survival...
An analyst from Barclays maintained Bristol-Myers Squibb (NYSE: BMY) at 'equalweight' with a price target of $64.00 from a prior price target of $65.00. Prior to this rating, Bristol-Myers...
Arbutus Biopharma (NASDAQ:ABUS) Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
An analyst from SVB MoffettNathanson initiated coverage of Bristol-Myers Squibb (NYSE: BMY) at 'market perform' with a price target of $66.00. Prior to this rating, Bristol-Myers Squibb...
Bristol Myers Squibb (NYSE:BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) in combination with platinum-based chemotherapy for the neoadjuvant...
An analyst from Daiwa Securities initiated coverage of Bristol-Myers Squibb (NYSE: BMY) at 'outperform' with a price target of $70.00. Prior to this rating, Bristol-Myers Squibb had 12...
Bristol Myers Squibb (NYSE:BMY) today announced that the European Commission (EC) has approved CAMZYOS® (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules) for the treatment of symptomatic...
Bristol Myers Squibb (BMY) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) to add positive data from the Phase 3...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
